Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity

A potential strategy for reduction of virus-infected cellular reservoirs

Douglas Tyler, S. David Stanley, John A. Bartlett, Dani P. Bolognesi, Kent J. Weinhold

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalJournal of Surgical Research
Volume79
Issue number2
DOIs
StatePublished - Oct 1998
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
HIV-1
Viruses
Lymphocytes
Antibodies
Cell- and Tissue-Based Therapy
HIV Infections
Interleukin-2
Blood Cells
Acquired Immunodeficiency Syndrome
Tissue Donors
Serum
Population

Keywords

  • ADCC
  • Interleukin-2
  • LAK cells
  • NK/K cells

ASJC Scopus subject areas

  • Surgery

Cite this

Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity : A potential strategy for reduction of virus-infected cellular reservoirs. / Tyler, Douglas; Stanley, S. David; Bartlett, John A.; Bolognesi, Dani P.; Weinhold, Kent J.

In: Journal of Surgical Research, Vol. 79, No. 2, 10.1998, p. 115-120.

Research output: Contribution to journalArticle

Tyler, Douglas ; Stanley, S. David ; Bartlett, John A. ; Bolognesi, Dani P. ; Weinhold, Kent J. / Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity : A potential strategy for reduction of virus-infected cellular reservoirs. In: Journal of Surgical Research. 1998 ; Vol. 79, No. 2. pp. 115-120.
@article{d3d3cc99206041f5bf5723a9921e3293,
title = "Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity: A potential strategy for reduction of virus-infected cellular reservoirs",
abstract = "Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.",
keywords = "ADCC, Interleukin-2, LAK cells, NK/K cells",
author = "Douglas Tyler and Stanley, {S. David} and Bartlett, {John A.} and Bolognesi, {Dani P.} and Weinhold, {Kent J.}",
year = "1998",
month = "10",
doi = "10.1006/jsre.1998.5415",
language = "English (US)",
volume = "79",
pages = "115--120",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lymphokine-activated killer (LAK) cell anti-HIV-1 adcc reactivity

T2 - A potential strategy for reduction of virus-infected cellular reservoirs

AU - Tyler, Douglas

AU - Stanley, S. David

AU - Bartlett, John A.

AU - Bolognesi, Dani P.

AU - Weinhold, Kent J.

PY - 1998/10

Y1 - 1998/10

N2 - Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

AB - Lymphocytes from HIV-1-seropositive and -seronegative individuals were examined to determine whether HIV-1 infection interfered with the ability to generate a lymphokine-activated killer (LAK) cell response. Following a 3- day ex vivo incubation in the presence of 1000 U/ml of recombinant interleukin-2, lymphocytes from seropositive individuals exhibited a LAK cell response which was equivalent to or greater than that of seronegative controls as measured against Daudi cell targets. LAK cells from seropositive and seronegative donors showed no specific cytolytic activity against gp120- coated or HIV-1-infected targets. However, in the presence of patient sera, significant levels of virus-specific LAK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) were observed. The level of this specific LAK cell-mediated ADCC was greater than that mediated under similar conditions by freshly isolated peripheral blood mononuclear cells. The greatest improvement in ADCC over baseline activity was seen with lymphocytes from AIDS patients after the 3-day ex vivo activation, suggesting that this patient population might benefit the most from adaptive LAK cell therapy.

KW - ADCC

KW - Interleukin-2

KW - LAK cells

KW - NK/K cells

UR - http://www.scopus.com/inward/record.url?scp=0032189347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032189347&partnerID=8YFLogxK

U2 - 10.1006/jsre.1998.5415

DO - 10.1006/jsre.1998.5415

M3 - Article

VL - 79

SP - 115

EP - 120

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -